The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
Open accessAbstract
BACKGROUND: Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. We set out to determine whether a multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously unscreened men with elevated total PSA. METHODS: The study cohort comprised 740 men in Göteborg, Sweden, undergoing biopsy during the first round of the European Randomized study of Screening for Prostate Cancer. We calculated the area-under-the-curve (AUC) for predicting prostate cancer at biopsy. AUCs for a model including age and PSA (the 'laboratory' model) and age, PSA and digital rectal exam (the 'clinical' model) were compared with those for models that also included additional kallikreins. RESULTS: Addition of free and intact PSA and hK2 improved AUC from 0.68 to 0.83 and from 0.72 to 0.84, for the laboratory and clinical models respectively. Using a 20% risk of prostate cancer as the threshold for biopsy would have reduced the number of biopsies by 424 (57%) and missed only 31 out of 152 low-grade and 3 out of 40 high-grade cancers. CONCLUSION: Multiple kallikrein forms measured in blood can predict the result of biopsy in previously unscreened men with elevated PSA. A multivariable model can determine which men should be advised to undergo biopsy and which might be advised to continue screening, but defer biopsy until there was stronger evidence of malignancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decision curve analysis: a novel method for evaluating prediction models
Vickers, A. J., & Elkin, E. B. (2006) · Medical Decision Making · doi:10.1177/0272989x06295361 · Cited by 6,341
Self-citationAssessment of diagnostic tests when disease verification is subject to selection bias
Begg, C. B., & Greenes, R. A. (1983) · Biometrics · doi:10.2307/2530820 · Cited by 708
Cited by
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Parekh, D. J., Punnen, S., Sjoberg, D. D., Asroff, S. W., Bailen, J. L., Cochran, J. S., Concepcion, R., David, R. D., Deck, K. B., Dumbadze, I., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.021 · Cited by 414
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Duffy, M. J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0693 · Cited by 267
Metadata
- Authors
- Vickers, A. J., Cronin, A. M., Aus, G., Pihl, C.-G., Becker, C., Pettersson, K., Scardino, P. T., Hugosson, J., & Lilja, H.
- Venue
- BMC Medicine
- Published
- 2008-07-08
- Volume
- 6
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2154558741
- Cited by
- 249
- References
- 2
- FWCI
- 11.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. https://app.cochat.ai/papers/10.1186/1741-7015-6-19
- The paper
- Vickers, A. J., Cronin, A. M., Aus, G., Pihl, C.-G., Becker, C., Pettersson, K., Scardino, P. T., Hugosson, J., & Lilja, H. (2008). A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Medicine. https://doi.org/10.1186/1741-7015-6-19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.